Anti-Thymoglobulin, Rabbit
Niemann-Pick Disease
Masonic Cancer Center, University of MinnesotaPhase 2/3Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Niemann-Pick Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Human Placental Derived Stem Cell New York Medical College | Phase 1 | CC |
Duoc-01 Joanne Kurtzberg, MD | Phase 1 | CC |
WATER O 15 National Institute of Neurological Disorders and Stroke (NINDS) | D | |
ogt918 National Eye Institute (NEI) | Phase 1 | NR |
Olipudase Alfa Sanofi | Phase 2/3 | NR |
Same molecule, other indications
Anti-Thymoglobulin, Rabbit is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →